Analysis of the Role of Stellate Cell VCAM-1 in NASH Models in Mice.
hepatic stellate cells (HSCs)
non-alcoholic fatty liver disease (NAFLD)
non-alcoholic steatohepatitis (NASH)
vascular cell adhesion molecule 1 (VCAM-1)
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Mar 2023
02 Mar 2023
Historique:
received:
22
12
2022
revised:
22
02
2023
accepted:
23
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) can progress to non-alcoholic steatohepatitis (NASH), characterized by inflammation and fibrosis. Fibrosis is mediated by hepatic stellate cells (HSC) and their differentiation into activated myofibroblasts; the latter process is also promoted by inflammation. Here we studied the role of the pro-inflammatory adhesion molecule vascular cell adhesion molecule-1 (VCAM-1) in HSCs in NASH. VCAM-1 expression was upregulated in the liver upon NASH induction, and VCAM-1 was found to be present on activated HSCs. We therefore utilized HSC-specific VCAM-1-deficient and appropriate control mice to explore the role of VCAM-1 on HSCs in NASH. However, HSC-specific VCAM-1-deficient mice, as compared to control mice, did not show a difference with regards to steatosis, inflammation and fibrosis in two different models of NASH. Hence, VCAM-1 on HSCs is dispensable for NASH development and progression in mice.
Identifiants
pubmed: 36902241
pii: ijms24054813
doi: 10.3390/ijms24054813
pmc: PMC10002755
pii:
doi:
Substances chimiques
Vascular Cell Adhesion Molecule-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 1862/3-1
Organisme : Hellenic Foundation for Research and Innovation
ID : 3222
Organisme : European Research Council
ID : DEMETINIL
Pays : International
Références
Handb Exp Pharmacol. 2016;233:221-49
pubmed: 25903417
Immunity. 2007 Jan;26(1):117-29
pubmed: 17239632
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411
pubmed: 28487545
J Clin Invest. 2021 Mar 15;131(6):
pubmed: 33476308
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
Nat Rev Immunol. 2022 Jul;22(7):429-443
pubmed: 34741169
Obes Rev. 2014 Jun;15(6):487-503
pubmed: 24612276
Nat Med. 2007 Nov;13(11):1324-32
pubmed: 17952090
Nat Immunol. 2017 Jun;18(6):654-664
pubmed: 28414311
Am J Pathol. 1999 Jan;154(1):153-67
pubmed: 9916930
J Innate Immun. 2022;14(1):31-41
pubmed: 34515137
Front Immunol. 2022 Aug 25;13:983255
pubmed: 36091042
Front Immunol. 2019 May 22;10:1078
pubmed: 31231358
Nat Commun. 2013;4:2823
pubmed: 24264436
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
J Hepatol. 2022 Oct;77(4):1136-1160
pubmed: 35750137
Cells. 2019 Nov 24;8(12):
pubmed: 31771248
J Immunol. 2011 May 15;186(10):5549-55
pubmed: 21460203
Int J Obes (Lond). 2017 Aug;41(8):1207-1213
pubmed: 28461687
Gut. 2021 May;70(5):940-950
pubmed: 32591434
J Hepatol. 2018 Aug;69(2):385-395
pubmed: 29572095
World J Gastroenterol. 2020 May 7;26(17):1993-2011
pubmed: 32536770
Cell. 2021 May 13;184(10):2537-2564
pubmed: 33989548
Int J Exp Pathol. 2013 Apr;94(2):93-103
pubmed: 23305254
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Am J Gastroenterol. 2012 Jun;107(6):811-26
pubmed: 22641309
Curr Obes Rep. 2022 Sep;11(3):126-143
pubmed: 35501558
Int J Mol Sci. 2021 Mar 26;22(7):
pubmed: 33810566
Int J Mol Sci. 2022 Jun 23;23(13):
pubmed: 35805998
Hepatology. 2003 May;37(5):1043-55
pubmed: 12717385
Nat Med. 2018 Jul;24(7):908-922
pubmed: 29967350
Hepatology. 2022 Apr;75(4):881-897
pubmed: 34519101
Am J Physiol Gastrointest Liver Physiol. 2011 Sep;301(3):G425-34
pubmed: 21659620